Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
This ia a single-arm, single-center, not-randomized, open-label phase II study. The purpose
of this study is to evaluate the efficacy and safety of Sintilimab (PD-1 antibody) combined
with Lenvatinib(TKI) for the treatment of local advanced hepatocellular carcinoma.